Engineering the early bone metastatic niche through human vascularized immuno bone minitissues

  • Biofabrication. 2021 Apr 26;13(3). doi: 10.1088/1758-5090/abefea.
Maria Vittoria Colombo  1  2 ,  Simone Bersini  1 ,  Chiara Arrigoni  1 ,  Mara Gilardi  3 ,  Veronica Sansoni  4 ,  Enrico Ragni  5 ,  Gabriele Candiani  2 ,  Giovanni Lombardi  4  6 ,  Matteo Moretti  1  7  8
Affiliations
  • 1. Regenerative Medicine Technologies Laboratory, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.
  • 2. Biocompatibility and Cell Culture Laboratory 'BioCell', Department of Chemistry, Materials and Chemical Engineering 'Giulio Natta', Politecnico di Milano, 20133 Milano, Italy.
  • 3. Institute of Pathology, University Hospital of Basel, Basel 4056, Switzerland.
  • 4. IRCCS Istituto Ortopedico Galeazzi, Laboratory of Experimental Biochemistry and Molecular Biology, 20161 Milano, Italy.
  • 5. IRCCS Istituto Ortopedico Galeazzi, Orthopedic Biotechnology Lab, 20161 Milano, Italy.
  • 6. Department of Athletics, Strength and Conditioning, Poznań University of Physical Education, Poznań 61-871, Poland.
  • 7. IRCCS Istituto Ortopedico Galeazzi, Cell and Tissue Engineering Laboratory, 20161 Milano, Italy.
  • 8. Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland.
Abstract

Bone metastases occur in 65%-80% advanced Breast Cancer patients. Although significant progresses have been made in understanding the biological mechanisms driving the bone metastatic cascade, traditional 2Din vitromodels and animal studies are not effectively reproducing Breast Cancer cells (CCs) interactions with the bone microenvironment and suffer from species-specific differences, respectively. Moreover, simplifiedin vitromodels cannot realistically estimate drug anti-tumoral properties and side effects, hence leading to pre-clinical testing frequent failures. To solve this issue, a 3D metastatic bone minitissue (MBm) is designed with embedded human osteoblasts, osteoclasts, bone-resident Macrophages, endothelial cells and breast CCs. This minitissue recapitulates key features of the bone metastatic niche, including the alteration of macrophage polarization and microvascular architecture, along with the induction of CC micrometastases and osteomimicry. The minitissue reflects breast CC organ-specific metastatization to bone compared to a muscle minitissue. Finally, two FDA approved drugs, doxorubicin and rapamycin, have been tested showing that the dose required to impair CC growth is significantly higher in the MBm compared to a simpler CC monoculture minitissue. The MBm allows the investigation of metastasis key biological features and represents a reliable tool to better predict drug effects on the metastatic bone microenvironment.

Keywords
3D in vitro models; bone metastases; bone–tumor interactions; breast cancer; drug efficacy.
Products